SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

Non-clear cell RCC is about 20-25% of all RCC diagnoses and usually has worse survival outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have been shown to help patients with non-clear cell RCC. KEYNOTE-427 is a phase 2 study that looked at the treatment of people with RCC with pembrolizumab as their […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer

An ongoing phase 2 study of a combination of two new medicines, camrelizumab (an immune checkpoint inhibitor) and famitinib (a novel tyrosine kinase inhibitor that targets a number of kinases) is looking at the safety and effectiveness of this combination in people with advanced or metastatic clear cell renal cell carcinoma (RCC). Previously treated people […]

read more

Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity

Recent evidence suggests that the bacteria in the gut (the gut microbiome) interacts with immune checkpoint inhibitors in metastatic renal cell carcinoma (RCC). In this study the bacterium Clostridium butyricum was investigated to see if it could modulate the gut microbiome in patients with metastatic RCC being treated with the nivolumab/ipilimumab combination and improve clinical […]

read more

ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]

read more

Risk of blood clots in cancer patients receiving immunotherapy

A recent study published in Blood has suggested that cancer patients who are being treated with immunotherapy, in particular immune checkpoint inhibitors are at high risk for blood clots (thromboembolism), especially blood clots in veins (venous thromboembolism). Although, the study does not show a causal link between immune checkpoint inhibitor therapy and blood clots. The […]

read more

EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more
Showing 1 to 10 of 194 results
  TOP